Skip to main content

A phase 2/3, randomized, open-label, parallel group, 2-arm, multicenter study investigating the efficacy and safety of intravenous administrations of anakinra, an interleukin-1(IL-1) receptor antagonist, added to standard of care, versus standard of care, in reducing hyper-inflammation and respiratory distress in patients with SARS- CoV-2 infection.

  • Protocol code: ANA-COVID-GEAS
  • EudraCT code: 2020-001825-29
  • Research group: Systemic Diseases
  • Service: Internal Medicine
  • Principal investigator:  Bujan Rivas, Segundo
  • Pathology: Certes malalties infeccioses i parasitàries
  • Phase: Fase III
  • Status: Recruiting volunteers